Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.

Any study that evaluates the utility of a prevention study must include a racially diverse population because it is possible that (1) there may still be mechanistic differences by which patients of different racial backgrounds progress to malignancy and (2) there may be significant socioeconomic barriers that effect treatment efficacy in different populations. 3.2.

also in 13,097 other papers